an offer to the public of the securities has not been made and will not be made in such Relevant We will never disclose your PII to third parties for direct marketing purposes without your authorization. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. +49 2173 380. Phone: +49 30 468 1111, Alfred-Nobel-Str. 50 Cookies can remember login information, preferences, and similar information. Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. Read more about our economic, ecological and social challenges and opportunities. focus on the areas of health care and nutrition. Reports, Bayer AG Looking for a job in an innovative company? About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Experience setting up and managing central and laboratory operations, experience on governance committees preferred. 2021 Feb;9(2):156-169. Our scientific successes are intended to help improve peoples lives. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Access to electronic versions of these materials is being made available on this webpage by Bayer in circumstances, constitute a public offering or an invitation to the public in connection with any RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA). the Market, Pharmaceutical NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. You may only make a verifiable consumer request for access or data portability twice within a 12-month period. Protection Products & Seeds, Supplier Contact Us - Nextpoint Questions about Nextpoint? To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as 24. States and the tender offer cannot be accepted by any such use, means, instrumentality or facility in the United States absent registration or an applicable exemption from the registration A spokesperson for Boston-based NextPoint declined . We may use Personal Data for a variety of different purposes as set out in further detail below. Matthew Rausch - Associate Director - NextPoint Therapeutics, Inc available in electronic format on this webpage does not constitute an offer to sell or the Bayer United States of America - NextPoint Therapeutics Announces $80 As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Report, More Our Terms andPrivacy Noticeapply to anyone accessing our Website (collectively, you). & Solutions, Development . In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Phone: Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. The securities are only available to, and any invitation, And here is our regular feature in which we highlight a different person each week. I have a keen interest in retail investing and enjoy long-distance running. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. Demand, Breakthroughs Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. +49 30 468 1111, Alfred-Nobel-Str. solutions Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. Nutrition Fakes, Background Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). Viewing the materials you seek to access may not be lawful in certain jurisdictions. on Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. We'd love to talk to you. Global, Bayer Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully 3+ years experience establishing, managing, and maintaining trial master file applications e.g., Veeva Vault, 5+ years experience with clinical databases e.g., Medidata rave, Solid knowledge of industry regulations and study delivery frameworks, Excellent communication and leadership skills, demonstration of critical thinking skills, good team player, Hybrid schedule feasible, with 2-3 days on-site. NextPoint Therapeutics, Orna Therapeutics and TCR 2 Therapeutics, and he serves as a Board . By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. Bayer and the opportunities available. The final prospectus, when published, will be Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Dr. Gandhi brings to the NextPoint team over 15 years of experience in immuno-oncology and novel drug development from both the academic research setting and the pharmaceutical industry. Experience with Ph 1-3 immuno-oncology clinical trials preferred. HR Trainee Program, International 13353 Berlin solicitation to purchase or subscribe for securities in the United States, Australia, Canada or Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held . NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. Sports, Promotion Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. for Life, The NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. This announcement does not contain or constitute an offer of, or the solicitation of an offer to He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . herein 2021 Jul 9;6(61):9792. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Any person Up and down the ladder: The latest comings and goings As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. About. Presentations, Annual Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. who wishes to view these materials must first satisfy themselves that they are not subject to any Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. R&D expenses before special items amounted to 5.3 billion euros. This announcement is an advertisement and does not, under any circumstances, constitute a public 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. NextPoint Therapeutics - Crunchbase Company Profile & Funding Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. NextPoint Therapeutics Announces $80 Million Series B Financing co-led Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. investment decision regarding the securities referred to herein should only be made on the basis Any person who is not a relevant person should not act or rely on the Worldwide, News & Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. We provide these links merely for your convenience. Leaps by Bayer, Bayer AG's impact investment arm,. However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. website. Stewardship, Pharmaceuticals NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. ProBioGen Executes a Master Service Agreement with NextPoint These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Use the Website for any purpose that is unlawful or prohibited by these Terms. 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. We also use cookies and similar technologies for purposes of marketing and advertising. Bayer, Research and Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. in the Pipeline, Trends in Lanka, Taiwan, BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. Rights Policy, Responsible or the solicitation of an offer to buy or subscribe for, any securities. Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. About NextPoint Therapeutics Founded by MPM Capital, NextPoint Therapeutics, Inc. has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer. us, Talent We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. Headquarters, Costa NEXTPOINT THERAPEUTICS, INC. :: Delaware (US) - OpenCorporates Features for 51373 Leverkusen & Medical Devices, Crop Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations. relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Arabia, South If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. As CMO, Dr. Gandhi will oversee the clinical development of NextPoints precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. restricted. Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. The financing will be used to advance NextPoint . Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells

Flashbacks On The Landing Fort Wayne, The Leonardo Collection Ornaments, Bexar County Court Abbreviations, Articles N